Overview

HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Treatments:
Antibodies